Susquehanna International Group
ECYT

Susquehanna International Group’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Susquehanna International Group’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-245,600
Closed -$4.36M – 10561
2018
Q3 		$4.36M Buy
245,600
+127,100
+107% +$2.18M ﹤0.01% 2845
2018
Q2 		$1.64M Sell
118,500
-21,900
-16% -$260K ﹤0.01% 4374
2018
Q1 		$1.28M Buy
140,400
+36,700
+35% +$202K ﹤0.01% 4743
2017
Q4 		$444K Buy
103,700
+70,100
+209% +$334K ﹤0.01% 6860
2017
Q3 		$47K Sell
33,600
-16,700
-33% -$23.3K ﹤0.01% 8556
2017
Q2 		$75K Buy
50,300
+10,800
+27% +$23.2K ﹤0.01% 8798
2017
Q1 		$102K Buy
39,500
+14,700
+59% +$34K ﹤0.01% 8385
2016
Q4 		$63K Sell
24,800
-8,400
-25% -$24.1K ﹤0.01% 9233
2016
Q3 		$103K Buy
33,200
+800
+2% +$2.49K ﹤0.01% 7930
2016
Q2 		$104K Sell
32,400
-13,400
-29% -$49.1K ﹤0.01% 8007
2016
Q1 		$142K Sell
45,800
-41,700
-48% -$136K ﹤0.01% 8246
2015
Q4 		$351K Buy
87,500
+11,200
+15% +$51.6K ﹤0.01% 7412
2015
Q3 		$349K Sell
76,300
-61,800
-45% -$323K ﹤0.01% 7773
2015
Q2 		$717K Buy
138,100
+19,000
+16% +$114K ﹤0.01% 6895
2015
Q1 		$746K Sell
119,100
-143,400
-55% -$828K ﹤0.01% 6336
2014
Q4 		$1.65M Sell
262,500
-79,800
-23% -$486K ﹤0.01% 4819
2014
Q3 		$2.08M Buy
342,300
+190,600
+126% +$1.3M ﹤0.01% 4547
2014
Q2 		$1M Sell
151,700
-334,300
-69% -$3.77M ﹤0.01% 6053
2014
Q1 		$11.6M Buy
486,000
+435,300
+859% +$6.31M 0.01% 1856
2013
Q4 		$542K Buy
50,700
+21,100
+71% +$233K ﹤0.01% 6562
2013
Q3 		$395K Sell
29,600
-28,900
-49% -$457K ﹤0.01% 6784
2013
Q2 		$768K Buy
+58,500
New +$789K ﹤0.01% 5411

Other funds holding ECYT

OTC
Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return
CA
Claro Advisors Boston, Massachusetts $953M AUM 24.79% 1-Year Est. Return

Susquehanna International Group's ECYT Position: Q2 2018 in Review

Susquehanna International Group sold out of Endocyte, Inc. Common Stock (ECYT) in Q2 2018, closing a stake of 499,801 shares — an estimated $5.93M sold.

Susquehanna International Group first reported a position in ECYT in Q2 2013 and held it in 19 quarters. The position peaked at $4.54M in Q1 2018. 114 funds tracked by Wall St. Rank hold ECYT as of Q2 2018.

  • Susquehanna International Group reported no remaining Endocyte, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • Susquehanna International Group sold 499,801 Endocyte, Inc. Common Stock shares in Q2 2018, an estimated $5.93M.
  • Susquehanna International Group first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 19 quarters.
  • Susquehanna International Group's Endocyte, Inc. Common Stock position peaked at $4.54M in Q1 2018.
  • 114 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q2 2018.

Based on Susquehanna International Group's 13F filing for Q2 2018, filed 14 Aug 2018.